Neonatal Herpes Simplex Virus Infection

  • Nazia KabaniEmail author
  • David Kimberlin


Many viruses are capable of infecting the central nervous system of neonates; however, herpes simplex virus (HSV) is among the most severe and has significant mortality and morbidity associated with it. Fortunately, HSV is treatable utilizing the commercially available antiviral drug acyclovir. Neonatal HSV infection is usually acquired in the peripartum period, which enhances the likelihood that antiviral therapy can be beneficial since viral damage is of a relatively short duration compared with injury to the developing fetal brain from viruses such as rubella, cytomegalovirus, and Zika virus that primarily are acquired in utero. Studies conducted over several decades have advanced our knowledge of the impact of antiviral therapy on neonatal HSV disease outcomes. Consequently, many neonates now are effectively treated and experience no or lesser long-term sequelae of this potentially devastating infection.


Acyclovir Encephalitis Hepatitis Herpes simplex virus Neonatal infection 


  1. 1.
    Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357:1513–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991;324:1247–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Brown ZA, Vontver LA, Benedetti J, et al. Effects on infants of a first episode of genital herpes during pregnancy. N Engl J Med. 1987;317:1246–51.CrossRefPubMedGoogle Scholar
  4. 4.
    Corey L, Wald A. Genital herpes. In: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P, Wasserheit JN, editors. Sexually transmitted diseases. 3rd ed. New York: McGraw-Hill; 1999. p. 285–312.Google Scholar
  5. 5.
    Nahmias AJ, Josey WE, Naib ZM, et al. Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol. 1971;110:825–37.CrossRefPubMedGoogle Scholar
  6. 6.
    Brown ZA, Wald A, Morrow RA, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA. 2003;289:203–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Yeager AS, Arvin AM. Reasons for the absence of a history of recurrent genital infections in mothers of neonates infected with herpes simplex virus. Pediatrics. 1984;73:188–93.PubMedGoogle Scholar
  8. 8.
    Prober CG, Sullender WM, Yasukawa LL, et al. Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med. 1987;316:240–4.CrossRefPubMedGoogle Scholar
  9. 9.
    Yeager AS, Arvin AM, Urbani LJ, et al. Relationship of antibody to outcome in neonatal herpes simplex virus infections. Infect Immun. 1980;29:532–8.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Parvey LS, Ch'ien LT. Neonatal herpes simplex virus infection introduced by fetal-monitor scalp electrodes. Pediatrics. 1980;65:1150–3.PubMedGoogle Scholar
  11. 11.
    Kaye EM, Dooling EC. Neonatal herpes simplex meningoencephalitis associated with fetal monitor scalp electrodes. Neurology. 1981;31:1045–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Whitley RJ. Herpes simplex viruses. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE, editors. Fields virology. 3rd ed. Philadelphia: Lippincott-Raven; 1996. p. 2297–342.Google Scholar
  13. 13.
    Anonymous. ACOG practice bulletin. Management of herpes in pregnancy. Number 8 October 1999. Clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet. 2000;68:165–73.CrossRefGoogle Scholar
  14. 14.
    Whitley RJ, Corey L, Arvin A, et al. Changing presentation of herpes simplex virus infection in neonates. J Infect Dis. 1988;158:109–16.CrossRefPubMedGoogle Scholar
  15. 15.
    Peng J, Krause PJ, Kresch M. Neonatal herpes simplex virus infection after cesarean section with intact amniotic membranes. J Perinatol. 1996;16:397–9.PubMedGoogle Scholar
  16. 16.
    Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 2001;108:230–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Kimberlin DW, Lin CY, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 2001;108:223–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Whitley R, Arvin A, Prober C, et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med. 1991;324:444–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. N Engl J Med. 1991;324:450–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Whitley RJ, Nahmias AJ, Soong SJ, et al. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics. 1980;66:495–501.PubMedGoogle Scholar
  21. 21.
    Whitley RJ. Herpes simplex virus infections. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infants. 3rd ed. Philadelphia: W.B. Saunders Company; 1990. p. 282–305.Google Scholar
  22. 22.
    Sullivan-Bolyai JZ, Hull HF, Wilson C, et al. Presentation of neonatal herpes simplex virus infections: implications for a change in therapeutic strategy. Pediatr Infect Dis. 1986;5:309–14.CrossRefPubMedGoogle Scholar
  23. 23.
    Arvin AM, Yeager AS, Bruhn FW, et al. Neonatal herpes simplex infection in the absence of mucocutaneous lesions. J Pediatr. 1982;100:715–21.CrossRefPubMedGoogle Scholar
  24. 24.
    Whitley RJ, Yeager A, Kartus P, et al. Neonatal herpes simplex virus infection: follow-up evaluation of vidarabine therapy. Pediatrics. 1983;72:778–85.PubMedGoogle Scholar
  25. 25.
    American Academy of Pediatrics. Herpes simplex. In: Brady TD, Jackson MA, Long SS, Kimberlin DW, editors. Red book: 2015 report of the committee on infectious diseases. 30th ed. American Academy of Pediatrics: Elk Grove Village, IL; 2015. p. 432–43.Google Scholar
  26. 26.
    Englund JA, Fletcher CV, Balfour HH Jr. Acyclovir therapy in neonates. J Pediatr. 1991;119:129–35.CrossRefPubMedGoogle Scholar
  27. 27.
    Kimberlin DW, Lakeman FD, Arvin AM, et al. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. J Infect Dis. 1996;174:1162–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Kimberlin DW. Advances in the treatment of neonatal herpes simplex infections. Rev Med Virol. 2001;11:157–63.CrossRefPubMedGoogle Scholar
  29. 29.
    Kimberlin DW, Whitley RJ, Wan W, et al. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med. 2011;365:1284–92.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Pediatric Infectious Diseases, Department of PediatricsUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations